The emerging psychedelic drug sector represents the most lucrative opportunities in life sciences today. We compare and contrast six of the drug R&D leaders.
Exploring the companies and themes that make up this emerging and exciting new sector
Third California City Seeks To Decriminalize Psychedelics
Another California city is pursuing a resolution to decriminalize psychedelics, with an Arcata City Council member agreeing to sponsor the measure.
Study suggests psychedelic users reframe “bad trips” into positive experiences through detailed narratives
A study published in the International Journal of Drug Policy asked psychedelic drug users to share their experiences with drug use, and particularly, their experiences with “bad trips.”
Harvard University Launches First-Of-Its-Kind Psychedelics Policy Center
Harvard Law School on Wednesday announced the launch of a first-of-its-kind psychedelics policy center that it hopes will inform legislation and help clinicians navigate this burgeoning medical space as reform continues to advance.
The Mental Health Pandemic Soars Into Focus, Psychedelics In The Spotlight
As the Mental Health Pandemic spirals out of control, we see a positive sign: the mainstream media has finally noticed it.
Cybin Announces Positive Pre-Clinical Results With Multiple Proprietary Psychedelic Molecules and Adelia Milestone Achievement
In pre-clinical testing, multiple proprietary molecules "showed consistent positive results when compared to the parent molecule".
COMPASS Pathways completes COMP360 psilocybin therapy administration for 216 patients in large-scale phase IIb psilocybin therapy trial for treatment-resistant depression
Compass Pathways completes the world's largest psilocybin-based clinical trial as the 216th patient in its trial completed their treatment.
Cybin Inc. Releases Annual Financials and Provides Business Highlights
Cybin Inc releases its full-year financial results for the fiscal year ended March 31, 2021 and provides business highlights.
Psyched Wellness Commences Next Pre-Clinical Study on AME-1
Psyched Wellness announces its latest pre-clinical study on AME-1.
MindMed Included in FTSE Russell 3000® Index
MindMed officially announces its inclusion in the FTSE Russell 3000.
Use of mescaline may facilitate unintended improvements in several psychiatric conditions, study suggests
The use of mescaline, a psychedelic substance derived from the peyote cactus, appears to be associated with improvements in depression and anxiety, according to a new preliminary study published in the journal ACS Pharmacology & Translational Science.
Psychedelic Medicine: Will The High Always Be Part Of The Therapy?
Psychedelic Stock Watch explains why astute investors will put their dollars into both "experiential" and non-psychoactive psychedelic drug R&D.